• Algorae executes Licence & Supply Agreement with Torrent Pharmaceuticals for two generic prescription molecules in Australia and New Zealand
• Phased commercialisation strategy includes products with existing registrations and those requiring new TGA registrations
• Torrent responsible for product development and manufacturing, Algorae to lead commercialisation activities in ANZ

Algorae Pharmaceuticals Ltd (ASX: 1AI) has executed a Licence & Supply Agreement (LSA) with Torrent Pharmaceuticals Limited (NSE: TORNTPHARM, BSE: 500420) for the commercialisation of two generic prescription molecules in Australia and New Zealand (ANZ). The agreement provides for a phased commercialisation approach, with Phase 1 targeting products supported by existing regulatory registrations to enable earlier market entry, and Phase 2 focusing on products requiring new TGA registrations to support a longer-term launch pipeline. The LSA also establishes a strategic framework for the parties to consider additional molecules from Torrent's product portfolio in future phases, subject to mutual agreement and regulatory considerations. Under the agreement, Torrent is responsible for product development and GMP compliant manufacturing, while Algorae, through its wholly owned subsidiary AlgoraeRx Pty Ltd, is expected to lead the ANZ commercialisation activities, including market access, pricing, reimbursement, sales, and distribution. The commercial terms of the agreement remain confidential, and Algorae will update shareholders on submission timing, anticipated launch windows, and expected revenue contribution as the phased commercialisation program advances.

The LSA provides a framework to consider additional molecules in future phases from Torrent's product portfolio, subject to mutual agreement and regulatory, commercial, and strategic considerations.